Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90.

Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential molecular therapeutic agents for the treatment of cancer. Here we describe the identification of novel small molecular weight inhibitors of Hsp90 using a fragment based approach. Fragments were selected by docking, tested in a biochemical assay and the confirmed hits were crystallized. Information gained from X-ray structures of these fragments and other chemotypes was used to drive the fragment evolution process. Optimization of these high μM binders resulted in 3-benzylindazole derivatives with significantly improved affinity and anti-proliferative effects in different human cancer cell lines.

[1]  Roderick E Hubbard,et al.  How well can fragments explore accessed chemical space? A case study from heat shock protein 90. , 2011, Journal of medicinal chemistry.

[2]  P. Bamborough,et al.  N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. , 2007, Bioorganic & medicinal chemistry letters.

[3]  Arlene Goldberg-Gist.  240TH ACS NATIONAL MEETING: BOSTON, Aug. 22–26 , 2010 .

[4]  Jason C. Young,et al.  Pathways of chaperone-mediated protein folding in the cytosol , 2004, Nature Reviews Molecular Cell Biology.

[5]  Gianni Chessari,et al.  Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. , 2010, Journal of medicinal chemistry.

[6]  Scott A Lesley,et al.  Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles. , 2005, Bioorganic & medicinal chemistry letters.

[7]  L. Pearl,et al.  Structure and mechanism of the Hsp90 molecular chaperone machinery. , 2006, Annual review of biochemistry.

[8]  Neal Rosen,et al.  Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.

[9]  L. Neckers,et al.  Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity , 2004, Investigational New Drugs.

[10]  N. Foloppe.  The benefits of constructing leads from fragment hits. , 2011, Future medicinal chemistry.

[11]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[12]  W. Pratt,et al.  Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery 1 , 2003, Experimental biology and medicine.

[13]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[14]  J. Caldwell,et al.  Crystal structures of human HSP90α-complexed with dihydroxyphenylpyrazoles , 2005 .

[15]  J. Peyrat,et al.  Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010 , 2011, Expert opinion on therapeutic patents.

[16]  Sreenath V. Sharma,et al.  Development of radicicol analogues. , 2003, Current cancer drug targets.

[17]  X. Barril,et al.  Structure-based discovery of a new class of Hsp90 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[18]  Xiong Cai,et al.  CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy , 2009, Clinical Cancer Research.

[19]  Mike Wood,et al.  4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. , 2007, Journal of medicinal chemistry.

[20]  D. Solit,et al.  Hsp90: the vulnerable chaperone. , 2004, Drug discovery today.

[21]  D. Kostrewa,et al.  Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.

[22]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[23]  X. Barril,et al.  Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. , 2004, Chemistry & biology.

[24]  R. Morimoto,et al.  Molecular chaperones and the stress of oncogenesis , 2004, Oncogene.

[25]  Jens Sadowski,et al.  A hybrid approach for addressing ring flexibility in 3D database searching , 1997, J. Comput. Aided Mol. Des..

[26]  Gary Box,et al.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.

[27]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[28]  J. Veal,et al.  Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. , 2008, Bioorganic & medicinal chemistry letters.

[29]  Gabriela Chiosis,et al.  Discovery and development of heat shock protein 90 inhibitors. , 2009, Bioorganic & medicinal chemistry.

[30]  P. Workman,et al.  HSP90 as a new therapeutic target for cancer therapy: the story unfolds , 2002, Expert opinion on biological therapy.

[31]  S. Lakhani,et al.  Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Kamal,et al.  Therapeutic and diagnostic implications of Hsp90 activation , 2004, Trends in Molecular Medicine.

[33]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[34]  Gabriela Chiosis,et al.  Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. , 2006, Journal of medicinal chemistry.

[35]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.